Avingtrans plc Employee & PDMR Share Incentive Awards

Avingtrans plc

Avingtrans plc (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced that on 21 November 2023, the Board of Avingtrans, in accordance with the Company’s Share Option Plan, granted options over 606,000 ordinary shares of 5p each in the Company with an exercise price of 390.0 pence per Ordinary Share. The following Option Awards were granted to Directors:

DirectorNumber of Ordinary Shares subject to Option Awards
Steve McQuillan180,000
Stephen King160,000

Furthermore Austen Adams, Managing Director of the Group’s PSRE Division and a PDMR of the Company, has been granted Option Awards over a total of 110,000 Ordinary Shares.

The Option Awards may not be exercised until 3 years from the date of grant and are subject to a performance condition, being the increase in the Company’s adjusted EPS must be at least equal to the increase in RPI over the vesting period.

Avingtrans plc designs, manufactures and supplies original equipment, systems and associated aftermarket services to the energy, medical and industrial markets worldwide. 

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Avingtrans Plc Building Momentum in Nuclear and Medical Imaging as Margins Surge (Video)

Avingtrans delivered improved margins and earnings in the first half, supported by stronger aftermarket activity and disciplined debt control. While revenue was flat year-on-year, management expects the usual second-half weighting to return, aided by nuclear contracts and rising data centre cooling demand. With Adaptix now FDA approved and US distributors appointed, medical imaging enters a critical commercial phase alongside growing exposure to AI-driven nuclear build-out.

Avingtrans reports higher interim profit and strong FY26 visibility

Avingtrans PLC reported flat first-half revenue of £78.1m for the six months to 30 November 2025, with adjusted EBITDA up 10.4% to £9.6m and adjusted profit before tax rising 27.1% to £5.7m.

Avingtrans appoints Stuart Gall as CEO of Medical and Industrial Imaging division

Avingtrans plc has announced that Stuart Gall officially assumed the role of Chief Executive Officer of its medical and industrial imaging division on 1 January 2026.

Avingtrans subsidiary Adaptix gains FDA clearance for Ortho350

Avingtrans reported that its subsidiary Adaptix has received FDA 510(k) clearance for the Ortho350, a compact 3D orthopaedic imaging system designed for point of care use.

Avingtrans CEO on record revenue and strong order book momentum for FY25 (LON:AVG)

Avingtrans has delivered record revenue of £156.4 million for FY25, with Chief Executive Officer Steve McQuillan highlighting robust order book growth, major contract wins, and increasing demand across energy, defence, infrastructure and medical divisions.

Avingtrans appoints Stuart Gall as CEO of medical imaging division

Avingtrans Plc has announced the appointment of Stuart Gall as Divisional Chief Executive Officer of its medical imaging businesses, including Adaptix and Magnetica, effective on or before 10 March 2026.

    Search